Literature DB >> 6790480

Serological, functional, and immunochemical characterization of a monoclonal antibody (MoAb Q2/70) to human Ia-like antigens.

V Quaranta, F Indiveri, M C Glassy, A Ng, C Russo, G A Molinaro, M A Pellegrino, S Ferrone.   

Abstract

Serological and immunochemical studies showed that monoclonal antibody Q2/70 (MoAb Q2/70), produced by the hybridoma technique, is specific for human Ia-like antigens. This antibody recognizes an antigenic determinant which is different from those defining the serologic polymorphism of Ia-like antigens, and is expressed on subsets of human Ia-like molecules and on lymphoid cells from other species. MoAb Q2/70 inhibits unidirectional MLRs* between allogenic human lymphocytes, but not between murine and human lymphocytes. In ADCC* assays. MoAb Q2/70 mediates lysis of cultured human B lymphoid cells RPMI 4098, effected by murine splenocytes. The antibody is suitable to isolate immunologically functional B lymphocytes from human peripheral blood.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6790480     DOI: 10.1016/0198-8859(80)90016-6

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  3 in total

1.  Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6 and Q5/13) on human Ia-like alloantigens and on their subunits.

Authors:  V Quaranta; N Tanigaki; S Ferrone
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

2.  Effect of polyclonal and monoclonal HLA-DR xenoantibodies on xenogeneic mixed lymphocyte reactions.

Authors:  C Russo; V Quaranta; F Indiveri; M A Pellegrino; S Ferrone
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

3.  Differential effect of tumour necrosis factor on human thymocyte subpopulations.

Authors:  M A Muñoz-Fernández; F X Pimentel-Muiños; A González; F Gambon; L Alvarez-Vallina; M Fresno
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.